OncoCyte Corporation

NASDAQ: OCX · Real-Time Price · USD
3.20
0.47 (17.22%)
At close: Jun 17, 2025, 3:59 PM

OncoCyte Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
3.84M 1.88M 709K 1.02M 1.38M 1.5M -2.36M -1.77M -169K 958K 8.1M 8.06M 8.03M 7.73M 4.64M 4.21M 2.33M
Cost of Revenue
1.44M 1.14M 1.04M 1.16M 1.29M 1.07M -4.89M -2.88M -694K 976K 8.75M 8.41M 8.45M 7.54M 6.04M 4.79M 2.73M
Gross Profit
2.02M 360K -330K -132K 90K 435K 2.53M 1.11M 525K -18K -652K -344K -424K 188K -1.39M -574K -402K
Operating Income
-58.57M -57.56M -28.93M -21.93M -25.59M -26.03M -11.35M -14.06M -14.33M -18M -63.36M -67.74M -72.75M -74.21M -44.8M -37.44M -32.64M
Interest Income
n/a n/a n/a 117K 117K 117K 129K 12K 12K 12K n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-58.2M -60.66M -43.14M -36.14M -39.94M -24.86M 449K -2.4M -2.36M -18.61M -63.71M -68.18M -72.17M -73.36M -44.04M -37.02M -33.84M
Net Income
-58.2M -60.66M -43.14M -36.14M -39.94M -28.42M -57.76M -60.72M -60.42M -73.5M -64.06M -68.41M -70.86M -64.1M -34.52M -27.5M -26.12M
Selling & General & Admin
14.59M 13.79M 12.78M 12.37M 12.96M 13.55M 7.17M 13.18M 18.35M 23.14M 34.59M 33.8M 35.38M 33.5M 31.34M 29.47M 24.19M
Research & Development
10.11M 9.12M 9.75M 9.12M 9.1M 9.29M -1.07M 1.16M 4.3M 7.3M 19.71M 18.43M 15.4M 13.63M 10.84M 10.31M 11M
Other Expenses
35.77M 35.71M 7.12M -26K -42K 8K 30K 96K 112K 26K -21K -91K -75K -37K 6K 15K 19K
Operating Expenses
60.81M 58.95M 29.63M 21.45M 22.01M 22.8M 6.08M 14.32M 22.65M 30.44M 54.3M 52.24M 50.77M 47.13M 42.17M 39.78M 35.19M
Interest Expense
40K 84K 214K 300K 306K 302K 154K 51K 58K 77K 107K 143K 171K 209K 244K 272K 298K
Selling & Marketing Expenses
3.34M 2.22M 2.09M 1.76M 985K 1.6M 900K 594K 4.04M 6.58M 10.47M 13M 12.15M 11.17M 9.73M 8.37M 7.26M
Cost & Expenses
63.94M 61.78M 30.67M 22.61M 23.3M 23.86M 1.18M 11.44M 21.96M 31.41M 63.05M 60.64M 59.22M 54.67M 48.21M 44.57M 37.91M
Income Tax Expense
n/a n/a n/a n/a n/a 2.93M 2.93M 3.04M 2.78M 246K 343K 273K -1.26M -9.22M -9.47M -9.52M -7.66M
Shares Outstanding (Basic)
256.94K 13.07M 13.71M 12.87M 8.26M 8.26M 8.26M 7.11M 5.96M 5.94M 5.93M 5.65M 4.61M 4.55M 4.57M 4.49M 4.11M
Shares Outstanding (Diluted)
256.94K 13.07M 13.71M 12.87M 8.26M 8.26M 8.26M 7.11M 5.96M 5.94M 5.93M 5.65M 4.61M 4.61M 4.57M 4.49M 4.11M
EPS (Basic)
-29.23 -4.37 -4.38 -4.19 -5 -3.5 -9.2 -10 -10.25 -12.97 -13.21 -14.64 -15.56 -14.19 -8.18 -7.18 -7.61
EPS (Diluted)
-29.23 -4.37 -4.38 -4.19 -5 -3.5 -9.2 -10 -10.25 -12.97 -13.11 -14.54 -15.46 -14.09 -8.18 -7.18 -7.61
EBITDA
-57.43M -59.41M -31.22M -22.41M -26.09M -23.06M -23.06M -24.28M -22.91M -30.52M -60.29M -66.87M -71.33M -68.83M -41.28M -35.02M -33M
EBIT
-51.47M -60.58M -34.54M -26.2M -29.99M -14.91M 1.85M -315K 143K -9.21M -54.28M -60.74M -65.12M -73.15M -44.7M -37.66M -34.45M
Depreciation & Amortization
1.23M 1.56M 1.31M 1.4M 1.53M 1.67M 2.63M 3.57M 4.48M 5.23M 5.2M 5.08M 5M 4.32M 3.21M 3.05M 2.01M